C
Description
Clinical pharmaceutical company founded in 2014 in Delray Beach, FL. Develops CYR-064, intranasal theophylline formulation (PDE inhibitor), a potential first-to-market regenerative treatment for persistent smell loss (post-viral hyposmia). Phase 2 FLAVOR trial with 151 patients showed positive primary and secondary endpoint results.